Could this rather large buy-out mean there is fire as well as smoke associated with experimental cancer stem cell treatment?

CLICK HERE to read about how Japanese drugs giant Dainippon Sumitomo Pharma will buy US biotechnology cancer specialist Boston Biomedical for a price that could hit $2.6 billion, the companies announced Thursday...

That's an awful lot of money to pay for a start-up with a therapy just starting Phase 3 trials.  Mmm... Wonder what's up?

Feel good and keep smiling!  Pat